Details

Autor(en) / Beteiligte

• Farahat, Ramadan Abdelmoez
• Khan, Sheharyar Hassan
• Memish, Ziad A.

Titel

Availability of monkeypox vaccinations for low and middle-income countries: Challenges and recommendations

Ist Teil von

• Travel medicine and infectious disease, 2022-11, Vol.50, p.102473-102473, Article 102473

Ort / Verlag

Netherlands: Elsevier Ltd

Erscheinungsjahr

2022

Quelle

Access via ScienceDirect (Elsevier)

Beschreibungen/Notizen

• Dear Editor, Since July 2022, the current monkeypox (MPX) multi-country outbreak has been declared a public health emergency of international concern (PHEIC) [1], and as of September 14, 2022, 59,147 confirmed and 489 suspected cases, including 22 deaths, have been reported to the World Health Organization (WHO). The ongoing outbreak is alarming because it is the first time since the discovery of monkeypox virus (MPXV) that there has been a widespread incidence of new cases in non-endemic countries outside of Africa. Since the first confirmed case of this outbreak in the UK in May 2022, the virus has spread globally, and the cases have been reported from 103 WHO member states [2]. Lessons may be learned from the COVID-19 vaccine development experiences, which resulted in a vast manufacturing capability globally [6]. Because there is practically only one MPX vaccine manufacturer, exporting technology to developing nations might assist secure enough supply for them while also contributing to global inventory [7].